Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)

Description

"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"

Conditions

Diabetes

Talk to us

Study Overview

On this page

Study Details

Study overview

"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)

Condition
Diabetes
Intervention / Treatment

-

Contacts and Locations

Stockbridge

Institute of Endocrinology Diabetes, Health & Hormones, Stockbridge, Georgia, United States, 30281

Las Vegas

Palm Research Center, Las Vegas, Nevada, United States, 89148

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
  • * Has at least one HbA1C (Hemoglobin a1c) measurement within three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use
  • * Subject is willing and able to use Dexcom CGM System according to approved product labeling
  • * Subject is willing and able to complete applicable patient reported outcome assessments/ surveys
  • * Subject is willing and able to comply with the protocol
  • * Subject is willing and able to comply with provider requirements for at least two provider encounters per year according to applicable clinical practice guidelines
  • * Subject or the subject's legally authorized representative must provide written informed consent prior to any study-related data collection or be enrolled under an IRB/EC approved waiver of consent
  • * Is contraindicated for a Dexcom CGM System per approved commercial labeling
  • * In the Investigator's opinion, the subject is not considered to be a suitable candidate

Ages Eligible for Study

2 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

DexCom, Inc.,

Study Record Dates

2028-06-30